All In Biotech

Drug Trial Radar · NCT07621471

IL-15 Enhanced NK Cell Therapy for Solid Tumors

A Single-Arm Clinical Study of IL-15 Enhanced Engineered NK Cells for Refractory Relapsed/Metastatic Solid Tumors

Last checked: Nov 20, 2026Latest source record: Nov 20, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

12

Planned (sponsor's estimate)

Start

Nov 18, 2026

Primary completion

Dec 31, 2028

Study completion Dec 31, 2028

Sponsor

Sponsor type
Industry
First posted
Jun 2, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Early phase 1
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 70 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

A single-arm, Phase 1 study evaluating safety, tolerability, and preliminary efficacy of IL-15 enhanced engineered NK cells in patients with refractory relapsed or metastatic solid tumors.

Conditions

  • Solid Tumors
  • Metastatic Cancer

Interventions

  • IL-15 enhanced engineered NK cellsDrug

    Genetically engineered NK cells expressing IL-15. Administered intravenously. See protocol for dose details.

  • IL-15 Enhanced Engineered NK CellsBiological

    Genetically engineered NK cells expressing IL-15

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Incidence of Dose-Limiting Toxicity (DLT)Time frame: Within 28 days after first infusion

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Xinqiao Hospital

    Chongqing, China · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.